Si Jing-Xing, Liu Zheng-Chuang, Gu Fang, Jin Xiaoli, Ma Ying-Yu
Department of Neurosurgery, Cancer Center, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang 310014, P.R. China.
Department of Paediatrics, Center for Reproductive Medicine, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang 310014, P.R. China.
Int J Oncol. 2025 Oct;67(4). doi: 10.3892/ijo.2025.5789. Epub 2025 Aug 24.
Brain tumors, particularly gliomas, are among the most lethal malignancies, with high mortality driven by a delayed diagnosis and limited therapeutic efficacy. A central challenge lies in the presence of the blood‑brain barrier (BBB), which severely impedes the delivery of systemically administered therapeutics to tumor sites. Addressing this clinical urgency, nanoparticle (NP)‑based delivery systems have emerged as a transformative strategy to enhance brain‑specific drug accumulation, minimize off‑target toxicity and improve treatment outcomes. The present review systematically examined the recent advances in nanocarrier technologies for targeted brain tumor therapy, including liposomes, solid lipid NPs, dendrimers, polymeric nanoplatforms and inorganic nanomaterials. The design principles, mechanisms for BBB traversal, therapeutic payload compatibility and tumor‑targeting capabilities of NP technologies demonstrated in preclinical models have also been highlighted. In addition to drug delivery, emerging applications of nanocarriers in gene therapy were explored and the impact of protein corona formation on NP behavior was discussed. Finally, current translational bottlenecks were identified and future design considerations to achieve clinically viable, precision‑targeted nanomedicines for brain tumors were outlined.
脑肿瘤,尤其是胶质瘤,是最致命的恶性肿瘤之一,其高死亡率是由诊断延迟和治疗效果有限所致。一个核心挑战在于血脑屏障(BBB)的存在,它严重阻碍了全身给药的治疗药物输送到肿瘤部位。为应对这一临床紧迫性,基于纳米颗粒(NP)的递送系统已成为一种变革性策略,以增强脑特异性药物蓄积、将脱靶毒性降至最低并改善治疗效果。本综述系统地研究了用于靶向脑肿瘤治疗的纳米载体技术的最新进展,包括脂质体、固体脂质NP、树枝状大分子、聚合物纳米平台和无机纳米材料。还强调了在临床前模型中展示的NP技术的设计原则、穿越血脑屏障的机制、治疗载荷兼容性和肿瘤靶向能力。除了药物递送,还探讨了纳米载体在基因治疗中的新兴应用,并讨论了蛋白质冠形成对NP行为的影响。最后,确定了当前的转化瓶颈,并概述了未来的设计考虑因素,以实现临床上可行的、针对脑肿瘤的精准靶向纳米药物。